ArticleBlood2007
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.
Article in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 95 citations in OpenAlex.
- CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.The Journal of clinical investigation · 2020Trial
- Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell.EMBO molecular medicine · 2011Trial
- Cell of origin epigenetic priming determines susceptibility to Tet2 mutation.Nature communications · 2024Article
- Safety and efficacy of CRISPR-based non-viralEClinicalMedicine · 2023Article
- Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages.Molecular therapy. Methods & clinical development · 2022Article
- Clonal Hematopoiesis, Cardiovascular Diseases and Hematopoietic Stem Cells.International journal of molecular sciences · 2020Review
- Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model.Oncotarget · 2017Article
- A Lentiviral Fluorescent Genetic Barcoding System for Flow Cytometry-Based Multiplex Tracking.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.The Journal of clinical investigation · 2016Review
- Integration site and clonal expansion in human chronic retroviral infection and gene therapy.Viruses · 2014Review
- Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders.Human gene therapy · 2014Review
- Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.Stem cells translational medicine · 2014Review
- Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation.Experimental hematology · 2014Article
- Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.Cancer cell · 2013Article
- Identification of Hematopoietic Stem Cell Engraftment Genes in Gene Therapy Studies.Journal of stem cell research & therapy · 2013Article
- Transgenic sheep generated by lentiviral vectors: safety and integration analysis of surrogates and their offspring.Transgenic research · 2013Article
- Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.Gene therapy · 2013Review
- Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells.Leukemia · 2013Article
- Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.Seminars in hematology · 2013Review
- Evaluating a ligation-mediated PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samples.Human gene therapy methods · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 3 countries.
Funding
Abstract
Evidence from model organisms and clinical trials reveals that the random insertion of retrovirus-based vectors in the genome of long-term repopulating hematopoietic cells may increase self-renewal or initiate malignant transformation. Clonal dominance of nonmalignant cells is a particularly interesting phenotype as it may be caused by the dysregulation of genes that affect self-renewal and competitive fitness. We have accumulated 280 retrovirus vector insertion sites (RVISs) from murine long-term studies resulting in benign or malignant clonal dominance. RVISs (22.5%) are located in or near (up to 100 kb [kilobase]) to known proto-oncogenes, 49.6% in signaling genes, and 27.9% in other or unknown genes. The resulting insertional dominance database (IDDb) shows substantial overlaps with the transcriptome of hematopoietic stem/progenitor cells and the retrovirus-tagged cancer gene database (RTCGD). RVISs preferentially marked genes with high expression in hematopoietic stem/progenitor cells, and Gene Ontology revealed an overrepresentation of genes associated with cell-cycle control, apoptosis signaling, and transcriptional regulation, including major "stemness" pathways. The IDDb forms a powerful resource for the identification of genes that stimulate or transform hematopoietic stem/progenitor cells and is an important reference for vector biosafety studies in human gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.